Overview

Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy

Status:
Not yet recruiting

Trial end date:
2029-09-01

Target enrollment:

Participant gender:

Summary

The purpose of the EXPAND study is to assess the safety and clinical efficacy of ALLO-647 combined with fludarabine and cyclophosphamide compared to fludarabine and cyclophosphamide alone in a lymphodepletion regimen prior to ALLO-501A CAR T therapy in adults with relapsed or refractory large B-cell lymphoma

Phase:

Phase 2

Details

Lead Sponsor:

Allogene Therapeutics

Treatments:

Cyclophosphamide
Fludarabine